Oxford Biomedica reports 36% decline in revenues for 2023
LONDON: Oxford Biomedica plc, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has released its preliminary financial results for the year...
Oxford Biomedica transforms into a pure-play CDMO in cell and gene therapy
LONDON, UK: Oxford Biomedica, a leading cell and gene therapy CDMO, has announced a business update for the year ending 31 December 2023. The update...
Oxford Biomedica to acquire 80% stake in AAV Manufacturing and Innovation Business
LONDON, UK: Oxford Biomedica has entered into an agreement with Homology Medicines Inc. to acquire an 80 per cent ownership interest in a newly formed...
Oxford Biomedica signs development & supply agreement with Boehringer Ingelheim
OXFORD: Oxford Biomedica has signed a new three year Development & Supply Agreement (DSA) with Boehringer Ingelheim for the manufacture and supply of various types...
Oxford Biomedica signs 5-year collaboration agreement with the Vaccines Manufacturing and Innovation Centre
OXFORD: Oxford Biomedica has signed a Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organisation established to provide the UK’s first...
Oxford Biomedica receives MHRA approval for the first two manufacturing suites in Oxbox
OXFORD: Oxford Biomedica plc has announced the successful outcome of their recent UK Medicines & Healthcare products Regulatory Agency (MHRA) inspection, resulting in the issue...